News
Boehringer Ingelheim and Eli Lilly announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta to include use in combination with ...
Boehringer Ingelheim and Eli Lilly announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta to include use in combination with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback